Videos

Nisha Mohindra, MD, and Christopher Towe, MD, define the term “multidisciplinary team” and explain why early-stage NSCLC care requires a diverse group of specialists. They also discuss the function and value of this collaborative model in guiding treatment plans. Sponsored by Bristol Myers Squibb.

The panel shares insights on the progress in early-stage non-small cell lung cancer treatment and the potential role of neoadjuvant therapy. Sponsored by Bristol Myers Squibb.

Nisha Mohindra, MD, and Christopher Towe, MD, discuss what early-stage non-small cell lung cancer treatment options have looked like in the past and a more recent treatment option, neoadjuvant therapy. Sponsored by Bristol Myers Squibb.

After Danielle Hicks introduces the panelists, Nisha Mohindra, MD, and Christopher Towe, MD, provide an overview of what an early-stage non-small cell lung cancer diagnosis means and how it is diagnosed. Sponsored by Bristol Myers Squibb.

Panelists discuss how the landscape of treatment options for advanced prostate cancer has evolved, highlighting the importance of understanding current therapies to optimize patient outcomes.

Panelists discuss how sharing personal experiences with diagnosis helps illuminate the critical questions patients should ask their care teams and the pivotal role oncologists play in guiding treatment decisions.

An expert discussed the importance of patients learning about their specific type of breast cancer to understand potential treatment options.

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy for EGFR-mutated non-small cell lung cancer.

In this on-demand webinar series, CURE partnered with SHARE Cancer Support to learn more about other challenges of breast cancer outside of treatment.

In this on-demand webinar series, CURE partnered with SHARE Cancer Support to learn more about emotional well-being as a patient and survivor of breast cancer.

Asking physicians how they perform less-invasive surgeries for breast cancer can help reassure patients that their lymphedema risk is kept in mind.

In this on-demand webinar series, CURE partnered with SHARE Cancer Support to learn more about experiences with cancer from two breast cancer survivors.

An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.

Panelists discuss how the PSA test is conducted and interpreted, and clarify the definitions of high-risk and advanced prostate cancer types, including their implications for prognosis and subsequent treatment decisions.

Panelists discuss how identifying the right candidates for prostate cancer screening and understanding the role of routine screenings versus symptom-driven assessments are essential for early diagnosis and effective management.

An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.

The discussion will explore the impact of fixed-duration treatments on quality of life, benefits and challenges compared with continuous therapy, financial considerations, and lifestyle goals during and after treatment.

At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.

The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

The discussion will cover the current CLL treatment landscape, including first-line and later-line options; the medical experts will review first-line treatments, approach to treatment selection, factors influencing recommendations, and strategies for shared decision-making with patients.

Medical experts explain CLL’s slow progression and its impact on treatment timing, and they also discuss the watch-and-wait approach, patient concerns, and how to address anxiety about delaying treatment.

Dr. Partow Kebriaei explains what patients can expect before, during and after an allogeneic stem cell transplant to treat acute lymphoblastic leukemia.

For patients with MDS, close monitoring by doctors may help determine the appropriate timing to undergo stem cell transplants before the disease worsens.

Jim Plotkin shares his personal experience with CLL, including his initial symptoms, the diagnostic process, challenges faced, and advice for patients with newly diagnosed CLL. Medical experts discuss their approach to explaining CLL to new patients and inquire about essential patient education resources.